Due to Pfizer’s underperformance relative to the healthcare sector over the past year, Wall Street analysts remain cautious ...

The stock market can be quite turbulent. Growth stocks, while having tremendous potential, can also be risky, as we have seen this month. The once-hyped AI growth stocks plummeted as investors failed ...

PFE stock decreased 30.0% from a peak of $40.71 on January 23, 2020, to $28.49 on March 23, 2020, compared to a ...

Historical patterns indicate that abrupt fluctuations in the market can impact any firm, regardless of its seeming dominance.

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this ...

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With ...

Pfizer Inc. (NYSE:PFE) is one of the best immunotherapy stocks to buy according to hedge funds. On February 12, Daiwa ...

Pfizer Inc. delivered a 17% total return since early November, but fundamentals lag and valuation isn’t compelling. Read more ...

Pfizer faces multi-year headwinds from loss of exclusivity and COVID franchise decline, but management highlights transformative M&A and pipeline optionality. Learn more on PFE stock here.

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always ...